Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (TavIx)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
UNICANCER
ClinicalTrials.gov Identifier:
NCT00630032
First received: March 5, 2008
Last updated: December 9, 2013
Last verified: December 2013

March 5, 2008
December 9, 2013
September 2007
June 2014   (final data collection date for primary outcome measure)
Disease-free survival (DFS) defined as a local, regional, or metastatic relapse, a contralateral breast cancer, or a death of any cause [ Time Frame: at 5 years ] [ Designated as safety issue: No ]
Disease-free survival (DFS) defined as a local, regional, or metastatic relapse, a contralateral breast cancer, or a death of any cause at 5 years [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00630032 on ClinicalTrials.gov Archive Site
  • DFS for triple-negative and ER+/PR-/HER2- subgroups [ Time Frame: at 5 years ] [ Designated as safety issue: No ]
  • Distant metastasis-free survival for whole population and subgroups [ Time Frame: at 5 years ] [ Designated as safety issue: No ]
  • Event-free survival defined as local, regional, or metastatic relapse, a contralateral breast cancer, a second cancer, or death of any cause [ Time Frame: at 5 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: at 5 years ] [ Designated as safety issue: No ]
  • Toxicity as measured by CTC-AE scale version [ Time Frame: During treatment phase ] [ Designated as safety issue: Yes ]
  • Biotheque transcriptome and proteome analysis [ Time Frame: after survival analysis ] [ Designated as safety issue: No ]
  • Quality of life as measured by QlQ C30/Br23 [ Time Frame: During treatment phase ] [ Designated as safety issue: No ]
  • DFS at 5 years for triple-negative and ER+/PR-/HER2- subgroups [ Designated as safety issue: No ]
  • Distant metastasis-free survival for whole population and subgroups [ Designated as safety issue: No ]
  • Event-free survival defined as local, regional, or metastatic relapse, a contralateral breast cancer, a second cancer, or death of any cause [ Designated as safety issue: No ]
  • Overall survival at 5 years [ Designated as safety issue: No ]
  • Toxicity as measured by CTC-AE scale version [ Designated as safety issue: Yes ]
  • Biotheque transcriptome and proteome analysis [ Designated as safety issue: No ]
  • Quality of life as measured by QlQ C30 [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them after surgery may kill any tumor cells remaining after surgery. It is not yet known whether docetaxel is more effective than ixabepilone when given after surgery and combination chemotherapy in treating breast cancer.

PURPOSE: This randomized phase III trial is studying giving combination chemotherapy followed by docetaxel or ixabepilone to compare how well they work in treating patients who have undergone surgery for nonmetastatic breast cancer.

OBJECTIVES:

Primary

  • To evaluate the benefit from sequential administration of 3 courses of combination chemotherapy (FEC100) followed by 3 courses of ixabepilone versus docetaxel on the 5-year disease-free survival of women with nonmetastatic, poor-prognosis breast cancer.

Secondary

  • To compare the 5-year distant metastasis-free survival.
  • To compare the 5-year event-free survival.
  • To compare the 5-year overall survival.
  • To compare the safety profiles for the two chemotherapy regimens.
  • To identify and/or validate predictive-gene expression profiles of clinical response/resistance to the two treatment regimens.
  • To bank frozen and fixed tumor and frozen serum prospectively for future translational studies in both genomics and proteomics (transcriptome and proteome analyses, tissue array analyses).
  • To compare the cost-effectiveness of these 2 regimens.
  • To compare the quality-of-life of patients treated with these 2 regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to participating center, menopausal status (pre- vs post-menopausal), and tumor hormone-receptor status (triple-negative vs progesterone-receptor negative, HER negative, and estrogen-receptor [ER] positive). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive epirubicin hydrochloride IV, fluorouracil IV, and cyclophosphamide IV every 3 weeks in courses 1-3 and docetaxel IV alone every 3 weeks in courses 4-6.
  • Arm II: Patients receive treatment in courses 1-3 as in arm I and ixabepilone IV alone every 3 weeks in courses 4-6.

In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients also complete a quality of life questionnaire periodically.

After completion of study treatment, patients are followed periodically for up to 10 years.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
  • Drug: cyclophosphamide
    500 mg/m2 every 3 weeks
  • Drug: Docetaxel
    100 mg/m2 every 3 weeks
  • Drug: epirubicin hydrochloride
    100 mg/m2 every 3 weeks
  • Drug: fluorouracil
    500 mg/m2 every 3 weeks
  • Drug: ixabepilone
    40 mg/m2 every 3 weeks
  • Active Comparator: Arm A
    3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
    Interventions:
    • Drug: cyclophosphamide
    • Drug: Docetaxel
    • Drug: epirubicin hydrochloride
    • Drug: fluorouracil
  • Experimental: Arm B
    3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
    Interventions:
    • Drug: cyclophosphamide
    • Drug: epirubicin hydrochloride
    • Drug: fluorouracil
    • Drug: ixabepilone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
762
September 2017
June 2014   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

Inclusion criteria:

  • Histologically proven invasive unilateral breast cancer (regardless of the type)

    • Initial clinical condition compatible with complete initial resection
    • No residual macro or microscopic tumor after surgical excision
  • Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :

    • Stage II or III disease
    • pT > 20 mm (T1-4)
  • Patients must meet 1 of the following hormone-receptor criteria:

    • Node-positive patients: triple-negative* tumor (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+)
    • Node-negative patients: triple-negative* tumor only
  • NOTE: *Hormone-receptor negativity is defined as ER < 10% and PR < 10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative
  • Must be able to begin chemotherapy no later than day 49 after the initial surgery

Exclusion criteria:

  • Clinically or radiologically detectable metastases (M0)
  • Bilateral breast cancer or contralateral ductal carcinoma in situ
  • Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type
  • Any tumor ≥ T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)
  • HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive
  • Any clinically or radiologically suspect and non-explored damage to the contralateral breast

PATIENT CHARACTERISTICS:

Inclusion criteria:

  • Female
  • Pre- or postmenopausal
  • ECOG performance status 0-1
  • Peripheral neuropathy ≤ grade 1
  • Neutrophil count ≥ 2,000/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin > 9 g/dL
  • AST and ALT ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Total bilirubin ≤ 1.0 times ULN
  • Serum creatinine ≤ 1.5 times ULN
  • LVEF ≥ 50% by MUGA scan or echocardiography
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment

Exclusion criteria:

  • Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer
  • Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study
  • Clinically significant cardiovascular disease within the past 6 months including any of the following:

    • Unstable angina
    • Congestive heart failure
    • Uncontrolled hypertension (i.e., blood pressure > 150/90 mm Hg)
    • Myocardial infarction
    • Cerebral vascular accidents
  • Known prior severe hypersensitivity reactions to agents containing Cremophor EL
  • Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Patients deprived of liberty or placed under the authority of a tutor

PRIOR CONCURRENT THERAPY:

  • At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered
  • At least 3 weeks since prior major surgery and adequately recovered
  • No prior chemotherapy, hormonal therapy, or radiotherapy
  • More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:

    • Amiodarone
    • Clarithromycin
    • Amprenavir
    • Delavirdine
    • Voriconazole
    • Erythromycin
    • Fluconazole
    • Itraconazole
    • Ketoconazole
    • Indinavir
    • Nelfinavir
    • Ritonavir
    • Saquinavir
  • No concurrent participation in another therapeutic trial involving an experimental drug
Female
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   France
 
NCT00630032
PACS08 - UC-0140/0610, PACS-08/0610, 2006-006494-24, PACS08-Tavlx, BMS-UNICANCER-PACS-08/0610, AMGEN-UNICANCER-PACS-08/0610
Yes
UNICANCER
UNICANCER
Not Provided
Principal Investigator: Mario Campone, MD ICO Centre Regional Rene Gauducheau
UNICANCER
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP